Most Read

The Series C financing round was led by the Redmile Group, with participation by new investor Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral

The partnership is for up to 8 antibody therapeutics including ABL Bio’s biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma (I-Mab). The agreement showcases the

Under the partnership, AbCellera is applying its microfluidic single-cell screening platform to find novel antibodies which can be used for the development of new Chimeric Antigen Receptor (CAR)

Vor Biopharma is an immuno-oncology company pioneering haematopoietic stem cell (HSC) therapies for the treatment of haematological malignancies and affiliate of PureTech Health. This foundational patent is the

DarwinHealth is a precision-focused cancer medicine company, utilizing systems-biology derived algorithms to identify appropriate therapies for cancer patients and to systematically discover and prioritize the next generation of

In addition, Zymeworks granted BeiGene a license to Zymeworks’ proprietary Azymetric and EFECT platforms to develop and commercialize globally up to three other bispecific antibodies using the platforms.

To fill their drug pipelines, large pharmaceutical and biotechnology companies are buying promising drug compounds that have been developed by small biotech companies up to the point of

The companies will advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies. Through a

This approval is an important achievement for the company and most importantly, represents major progress for patients and physicians. Octapharma board member Olaf Walter said: “The development of